Gene Therapy Offers Lifelong Cholesterol Reduction
TL;DR Summary
An experimental gene therapy called VERVE-102, using base editing of the PCSK9 gene, shows promise in reducing LDL cholesterol in clinical trials, especially for those with familial hypercholesterolemia and premature coronary artery disease, with ongoing studies and potential for broad application.
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
4 min
vs 4 min read
Condensed
95%
772 → 41 words
Want the full story? Read the original article
Read on Live Science